Issue navigation
Volume 42, Issue suppl_3, November 2003
Evidence of value: assessing treatment outcomes in arthritis and pain
Introduction
Introduction
Rheumatology, Volume 42, Issue suppl_3, November 2003, Pages iii1–iii2, https://doi.org/10.1093/rheumatology/keg491
The effects of channelling bias on interpretation of observational studies
Channelling of patients taking NSAIDs or cyclooxygenase-2-specific inhibitors and its effect on interpretation of outcomes
Rheumatology, Volume 42, Issue suppl_3, November 2003, Pages iii3–iii10, https://doi.org/10.1093/rheumatology/keg492
Drug utilization and compliance
Drug utilization review of celecoxib in Ontario
Rheumatology, Volume 42, Issue suppl_3, November 2003, Pages iii11–iii16, https://doi.org/10.1093/rheumatology/keg493
Persistency of use of COX-2-specific inhibitors and non-specific non-steroidal anti-inflammatory drugs (NSAIDs) in Quebec
Rheumatology, Volume 42, Issue suppl_3, November 2003, Pages iii17–iii22, https://doi.org/10.1093/rheumatology/keg494
Underutilization of preventive strategies in patients receiving NSAIDs
Rheumatology, Volume 42, Issue suppl_3, November 2003, Pages iii23–iii31, https://doi.org/10.1093/rheumatology/keg495
Patient-centred issues: dyspepsia and post-operative pain
Measuring dyspepsia-related health in randomized trials: the Severity of Dyspepsia Assessment (SODA) and its use in treatment with NSAIDs and COX-2-specific inhibitors
Rheumatology, Volume 42, Issue suppl_3, November 2003, Pages iii32–iii39, https://doi.org/10.1093/rheumatology/keg496
The burden of acute postoperative pain and the potential role of the COX-2-specific inhibitors
Rheumatology, Volume 42, Issue suppl_3, November 2003, Pages iii40–iii52, https://doi.org/10.1093/rheumatology/keg497
Health economics of COX-2-specific inhibitors
Economic evaluation of oral valdecoxib versus diclofenac in the treatment of patients with rheumatoid arthritis in a randomized clinical trial
Rheumatology, Volume 42, Issue suppl_3, November 2003, Pages iii53–iii59, https://doi.org/10.1093/rheumatology/keg498
The use of health economic information by reimbursement authorities
Rheumatology, Volume 42, Issue suppl_3, November 2003, Pages iii60–iii63, https://doi.org/10.1093/rheumatology/keg499
Discussion and Concluding Remarks
Discussion and Concluding Remarks
Rheumatology, Volume 42, Issue suppl_3, November 2003, Pages iii64–iii67, https://doi.org/10.1093/rheumatology/keg500
